{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:33:51Z","timestamp":1787070831185,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Acute esophagitis (AE) is a commonly encountered side effect of curative thoracic radiotherapy (CTRT) for lung cancer patients. Nevertheless, its identification for widely used scoring systems depends on patients' statements. It is aimed to evaluate the correlation between the esophagus doses during CTRT and Grade 1\u20132 AE, weight change, and change in serum albumin (Alb) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>\n                      The data collected from 124 lung cancer patients treated with \u226560 Gy CTRT were evaluated retrospectively. Weight and serum Alb level difference of each patient, throughout CTRT, were calculated. The percentage of the esophagus volume receiving \u22655 Gy (V5), V10, V35, V50, and V60; the absolute esophagus volume receiving \u226560 Gy (V60(cc)); the length of esophagus receiving \u226560 Gy (L60); the average esophagus dose (D\n                      <jats:sub>mean<\/jats:sub>\n                      ); and the maximum esophagus dose (D\n                      <jats:sub>max<\/jats:sub>\n                      ) were the dose parameters calculated. The correlations were performed by Spearman's rank correlation coefficient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Grade 1 and Grade 2 AE were reported in 62 and 25 patients, respectively. All of the dose parameters were correlated with Grade 1\u20132 AE (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and weight loss (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 for all, except D\n                      <jats:sub>max<\/jats:sub>\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.018). Decrease in serum Alb level was significantly correlated with all the parameters, but V5 and V10. Receiver operating characteristic curve analysis was performed for five parameters with the highest correlation coefficient (V35, V50, V60(%), V60(cc), and D\n                      <jats:sub>mean<\/jats:sub>\n                      ), and the cutoff values were 39.5%, 28.17%, 2.21%, 0.5cc, and 26.04 Gy, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The correlation of the dose parameters that might be effective on Grade 1\u20132 AE with the weight loss and Alb loss was investigated, and the cutoff values corresponding to the best sensitivity and specificity were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_410_19","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T07:09:54Z","timestamp":1602227394000},"page":"94-98","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The esophageal dose\u2013volume parameters for predicting Grade I\u2013II acute esophagitis correlated with weight loss and serum albumin decrease in lung cancer radiotherapy"],"prefix":"10.4103","volume":"17","author":[{"given":"Zumrut Arda","family":"Kaymak Cerkesli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Elif","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Ozseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20241021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-16-20241021","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2004.12.025","article-title":"Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy","volume":"62","author":"Kim","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R3-16-20241021","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.07-1378","article-title":"American College of Chest Physicians. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Scott","year":"2007","journal-title":"Chest"},{"key":"R4-16-20241021","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R5-16-20241021","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.radonc.2013.04.012","article-title":"Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer","volume":"107","author":"Uyterlinde","year":"2013","journal-title":"Radiother Oncol"},{"key":"R6-16-20241021","first-page":"90","article-title":"Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer","volume":"9","author":"Choy","year":"1999","journal-title":"Semin Radiat Oncol"},{"key":"R7-16-20241021","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2008.09.010","article-title":"Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy","volume":"91","author":"Rose","year":"2009","journal-title":"Radiother Oncol"},{"key":"R8-16-20241021","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R9-16-20241021","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J Clin Oncol"},{"key":"R10-16-20241021","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0360-3016(93)90371-2","article-title":"Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials","volume":"27","author":"Cox","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-16-20241021","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1200\/jco.2004.22.90140.6098","article-title":"The NCI common terminology criteria for adverse events (CTCAE) v 3.0 is the new standart for oncology clinical trials","volume":"22","author":"Colevas","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-16-20241021","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-16-20241021","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.ijrobp.2009.05.070","article-title":"Radiation dose-volume effects in the esophagus","volume":"76","author":"Werner-Wasik","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-16-20241021","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijrobp.2006.04.022","article-title":"Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy","volume":"66","author":"Wei","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-16-20241021","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ijrobp.2005.04.004","article-title":"Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy","volume":"62","author":"Takeda","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-16-20241021","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ijrobp.2008.04.064","article-title":"Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy","volume":"73","author":"Rodr\u00edguez","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-16-20241021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/jrr\/rrx060","article-title":"Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy","volume":"59","author":"Mitsuyoshi","year":"2018","journal-title":"J Radiat Res"},{"key":"R18-16-20241021","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2004.06.014","article-title":"Dosimetric and clinical predictors for radiation-induced esophageal injury","volume":"61","author":"Ahn","year":"2005","journal-title":"Int J Radiat Oncols Biol Phys"},{"key":"R19-16-20241021","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.2147\/OTT.S174561","article-title":"Clinical, dosimetric, and position factors for radiation-induced acute esophagitis in intensity-modulated (chemo) radiotherapy for locally advanced non-small-cell lung cancer","volume":"11","author":"Huang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R20-16-20241021","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ijrobp.2012.01.071","article-title":"Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer","volume":"84","author":"Gomez","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-16-20241021","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.ijrobp.2012.03.027","article-title":"Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy","volume":"84","author":"Kwint","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-16-20241021","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.radonc.2010.09.028","article-title":"Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients","volume":"97","author":"Dehing-Oberije","year":"2010","journal-title":"Radiother Oncol"},{"key":"R23-16-20241021","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0360-3016(02)03937-8","article-title":"Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy","volume":"55","author":"Singh","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-16-20241021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.6004\/jnccn.2013.0084","article-title":"Non-small cell lung cancer. version 4.2019","volume":"11","author":"Ettinger","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R25-16-20241021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0360-3016(94)E0021-B","article-title":"A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: An interim toxicity analysis of the first 100 patients","volume":"31","author":"Ball","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-16-20241021","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.coc.0000256691.27796.24","article-title":"A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer","volume":"30","author":"Yuan","year":"2007","journal-title":"Am J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_410_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:19Z","timestamp":1787067439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_410_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_410_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}